Reuters logo
BRIEF-VBL Therapeutics and Nanocarrier signs agreement for VB-111 in Japan
2017年11月6日 / 中午12点28分 / 13 天前

BRIEF-VBL Therapeutics and Nanocarrier signs agreement for VB-111 in Japan

Nov 6 (Reuters) - Nanocarrier Co Ltd

* VBL Therapeutics and Nanocarrier Co Ltd sign exclusive agreement for VB-111 in Japan

* Vascular Biogenics Ltd - ‍Nanocarrier receives exclusive rights to VB-111 in Japan, VBLT retains rights in rest of world​

* Vascular - Pursuant to agreement, VBLT to supply nanocarrier with VB-111

* Vascular - Nanocarrier will be responsible for all regulatory, other clinical activities necessary for commercialization of VB-111 in Japan

* Vascular - VBLT receives up-front payment of $15 million & is entitled to receive greater than $100 million in development & commercial milestone payments​

* Vascular Biogenics Ltd - ‍VBLT will also receive tiered royalties on net sales in high-teens​

* Vascular Biogenics Ltd - ‍Other terms of agreement not disclosed​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below